Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. (BNTC) on October 11, 2023. The report addresses Item 5.02 regarding compensatory arrangements for certain officers related to performance during the fiscal year ended June 30, 2023.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific discretionary bonus payments approved by the Compensation Committee:
- Dr. Jerel Banks (Executive Chairman and CEO): $273,000
- Megan Boston (Executive Director): $116,928 (converted from AUD using a rate of 0.64 USD/AUD)
Material Changes
The filing reports the approval of discretionary bonuses for the fiscal year ending June 30, 2023. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies beyond the standard disclosure of the bonus approval.
Key Facts for Investor Verification
- Verify the total cash impact of the $389,928 in approved bonuses against the company's current cash reserves.
- Confirm the performance criteria used by the Compensation Committee to justify these discretionary payments for the fiscal year ended June 30, 2023.
- Review the company's most recent 10-K or 10-Q for comprehensive financial health metrics, as this 8-K does not provide them.